PTAB Invalidates Key Claims in Seer-Backed Proteomics Patent — Bruker Corporation

Event summary

U.S. Patent Trial and Appeal Board (PTAB) revoked central claims of U.S. Patent No. 11,435,360 owned by The Brigham and Women’s Hospital and exclusively licensed to Seer, Inc.
The PTAB invalidated Claim 1, which covered workflows using multiple nanoparticle types for protein detection.
PreOmics GmbH and Biognosys AG, subsidiaries of Bruker Corporation, prevailed in the IPR proceeding IPR2024-01473.
The patent challenge centered on the validity of fundamental concepts in proteomics workflows.
Biognosys Group maintains a vendor-neutral strategy in the mass spectrometry market.

The big picture

The PTAB's decision invalidating key claims in a Seer-backed patent underscores the ongoing intellectual property battles in the proteomics space. This victory for PreOmics and Biognosys, both subsidiaries of Bruker Corporation, could reshape competitive dynamics in the mass spectrometry market, particularly as the industry moves toward more integrated multiomics solutions. The outcome also highlights the importance of prior scientific literature in patent validity challenges, a trend likely to influence future IP strategies in biotechnology.

What we're watching

IP Strategy Shifts: How Seer, Inc. will respond to this patent loss and whether it will pursue further legal actions or shift its IP strategy.
Market Positioning: Whether PreOmics and Biognosys can leverage this victory to strengthen their market position in proteomics and multiomics.
Technological Innovation: The pace at which PreOmics and Biognosys can advance their high-performance sample preparation and software solutions in the wake of this legal win.